Real-Life Response to Biologics in Severe Asthma with Nasal Polyposis: Insights from the Belgian Severe Asthma Registry.

IF 4.6 2区医学 Q1 RESPIRATORY SYSTEM

Lung Pub Date : 2024-08-01 Epub Date: 2024-07-15 DOI:10.1007/s00408-024-00715-0

Femke Demolder, Eef Vanderhelst, Sylvia Verbanck, Florence Schleich, Renaud Louis, Guy Brusselle, Carine Sohy, Alain Michils, Rudi Peché, Charles Pilette, Shane Hanon

{"title":"Real-Life Response to Biologics in Severe Asthma with Nasal Polyposis: Insights from the Belgian Severe Asthma Registry.","authors":"Femke Demolder, Eef Vanderhelst, Sylvia Verbanck, Florence Schleich, Renaud Louis, Guy Brusselle, Carine Sohy, Alain Michils, Rudi Peché, Charles Pilette, Shane Hanon","doi":"10.1007/s00408-024-00715-0","DOIUrl":null,"url":null,"abstract":"Background: Nasal polyposis (NP) is a comorbidity of type 2 severe asthma (SA) which could influence response to SA biologics.Methods: We evaluated (super-) response in SA patients with (NP +) and without NP (NP-) enrolled in the Belgian Severe Asthma Registry (BSAR).Results: 914 patients, of whom 31% NP + , were included. At enrollment, NP + patients had higher annual exacerbation rates, higher number of emergency room visits and more elevated type 2 biomarkers. In the longitudinal subanalysis of 104 patients, both groups had significant and similar asthma responses to asthma biologics, except for a greater increase in FEV1 in the NP + group. Super-response was achieved in 33 patients (32%), irrespective of NP status or type of biologic.Conclusion: In conclusion, both NP + and NP - patients had positive treatment responses, with some able to achieve super-response. In SA patients with NP, a greater FEV1 improvement as compared to SA patients without NP was observed.","PeriodicalId":18163,"journal":{"name":"Lung","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lung","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00408-024-00715-0","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/15 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Nasal polyposis (NP) is a comorbidity of type 2 severe asthma (SA) which could influence response to SA biologics.

Methods: We evaluated (super-) response in SA patients with (NP +) and without NP (NP-) enrolled in the Belgian Severe Asthma Registry (BSAR).

Results: 914 patients, of whom 31% NP + , were included. At enrollment, NP + patients had higher annual exacerbation rates, higher number of emergency room visits and more elevated type 2 biomarkers. In the longitudinal subanalysis of 104 patients, both groups had significant and similar asthma responses to asthma biologics, except for a greater increase in FEV₁ in the NP + group. Super-response was achieved in 33 patients (32%), irrespective of NP status or type of biologic.

Conclusion: In conclusion, both NP + and NP - patients had positive treatment responses, with some able to achieve super-response. In SA patients with NP, a greater FEV₁ improvement as compared to SA patients without NP was observed.

Abstract Image

查看原文本刊更多论文

鼻息肉病重症哮喘患者对生物制剂的真实反应：来自比利时重症哮喘登记处的启示。

背景：鼻息肉病（NP）是2型重症哮喘（SA）的一种合并症，可能会影响对SA生物制剂的反应：我们评估了比利时重症哮喘登记处（BSAR）登记的患有（NP+）和不患有（NP-）鼻息肉的哮喘患者的（超级）反应：结果：共纳入 914 名患者，其中 31% 为 NP +。在登记时，NP + 患者的年恶化率较高，急诊就诊次数较多，2 型生物标志物升高较多。在对104名患者进行的纵向子分析中，两组患者对哮喘生物制剂的哮喘反应显著且相似，只是NP +组患者的FEV1增加更多。33名患者（32%）实现了超应答，与NP状态或生物制剂类型无关：总之，"NP+"和 "NP-"患者都对治疗产生了积极的反应，其中一些患者还达到了超级反应。在有 NP 的 SA 患者中，与没有 NP 的 SA 患者相比，FEV1 的改善幅度更大。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Lung 医学-呼吸系统

CiteScore

9.10

自引率

10.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Lung publishes original articles, reviews and editorials on all aspects of the healthy and diseased lungs, of the airways, and of breathing. Epidemiological, clinical, pathophysiological, biochemical, and pharmacological studies fall within the scope of the journal. Case reports, short communications and technical notes can be accepted if they are of particular interest.